Form 4: PepGen Reprices EVP Streck's Stock Options to $4.53

PepGen Inc. repriced 242,816 stock options for EVP Paul Streck, reducing the exercise price to $4.53 from $9.83, subject to retention.

Summary

• PepGen Inc.'s Board of Directors approved a repricing of outstanding stock options for Paul Streck, EVP, Head of R&D.
• The exercise price for 242,816 stock options was reduced from $9.83 to $4.53 per share.
• The repricing applies to options granted under the Issuer's 2020 Stock Plan, 2022 Stock Option and Incentive Plan, and 2024 Inducement Plan.
• The reduced exercise price is contingent upon the Reporting Person satisfying an applicable retention period; otherwise, the original exercise price will apply.
• The options vest 25% on the one-year anniversary of the Grant Date, with the remainder vesting in 36 equal monthly installments, subject to continued service.
• The transactions are exempt under SEC Rules 16b-6(d) and 16b-3.

Sentiment

Score: 7

Explanation: The repricing is a strong positive for the executive, significantly increasing the potential value of their options. For the company, it's a strategic move to retain key talent, which is generally positive for stability, though it carries a potential cost in terms of future dilution and shareholder perception.

Positives

• The repricing significantly reduces the exercise price for 242,816 stock options, providing a strong incentive for EVP Paul Streck.
• This action can serve as a retention mechanism for a key executive, potentially ensuring stability in leadership for R&D.
• The repricing aligns the executive's incentives more closely with potential future stock price recovery from the current lower valuation.

Negatives

• The repricing could be viewed as dilutive to existing shareholders if the options become more easily exercisable at a lower price, potentially increasing the number of outstanding shares.
• Shareholders might perceive this as a cost, as the company is effectively making it easier for an executive to profit from stock options, especially if the stock price does not recover significantly above the original strike price.

Risks

• The reduced exercise price is conditional on the Reporting Person satisfying an applicable retention period, introducing a potential risk if the executive does not meet this condition.
• The effectiveness of this incentive depends on the company's future stock performance and the executive's continued service.

Future Outlook

The repricing aims to re-incentivize a key executive, with the reduced exercise price contingent on satisfying a retention period. The options will vest over time, with 25% vesting on the one-year anniversary of the Grant Date and the remainder in 36 equal monthly installments, subject to continued service.

Industry Context

Stock option repricing is a strategy sometimes employed in the biotechnology sector, particularly when a company's stock price has experienced a significant decline. It serves to re-motivate and retain key talent, such as an EVP of R&D, by making their equity incentives more valuable and achievable, thereby aligning their long-term interests with the company's recovery and future growth.

Comparison to Industry Standards

• Repricing options is a common practice in industries like biotech where stock volatility can be high, and retaining key scientific and executive talent is crucial for long-term success.
• The magnitude of the repricing (over 50% reduction in strike price) suggests a significant effort to re-incentivize the executive, which is not uncommon when a company's stock has traded significantly below previous grant prices.
• Companies such as Biogen or Moderna have also utilized various equity compensation strategies, including adjustments, to retain top talent during periods of market fluctuation or strategic shifts, though specific repricing events vary by company and circumstance.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for increased future dilution if the repriced options are exercised, and a perceived cost of executive retention. However, retaining a key R&D executive could be seen as beneficial for long-term value creation.
• Employees: May signal the company's commitment to retaining key talent, potentially boosting morale or setting a precedent for future compensation adjustments.
• Executive (Paul Streck): Directly benefits from the significantly reduced exercise price, enhancing the value of his equity compensation and providing a strong incentive for continued service.

Next Steps

• Paul Streck must satisfy the applicable retention period to qualify for the reduced exercise price.
• The repriced options will begin vesting, with 25% on the one-year anniversary of the Grant Date and the remainder in 36 equal monthly installments, subject to continued service.

Key Dates

Keywords

Stock Options, Repricing, Executive Compensation, Form 4, PepGen Inc., PEPGEN, Paul Streck, EVP, R&D, Incentive Plan, Retention